Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma
10.3760/cma.j.issn.0529-567x.2010.05.011
- VernacularTitle:子宫内膜浆液性乳头状癌组织中Her-2/neu基因的扩增和蛋白表达及其意义
- Author:
Yulan REN
;
Huaying WANG
;
Xiaoyan ZHOU
;
Boer SHAN
;
Wentao YANG
;
Lei SHEN
;
Daren SHI
- Publication Type:Journal Article
- Keywords:
Endometrial neoplasms;
Carcinoma,papillary;
Genes,erbB-2;
Receptor,erbB-2;
Prognosis
- From:
Chinese Journal of Obstetrics and Gynecology
2010;45(5):367-371
- CountryChina
- Language:Chinese
-
Abstract:
Objective The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma ( UPSC) and to determine its prognostic value.Methods Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan.1996 to Jan.2006,were analysed retrospectively.CISH was performed to assess Her-2/neu gene amplification,and protein expression was evaluated by immunohistochemistry (IHC).The prognostic factors were analyzed by log-rank test or Cox proportional hazard model.Results Among 36 cases with UPSC,13 patients (36.1% ) showed moderate staining (++) to strong staining (+++) for Her-2/neu protein,while amplification of the Her-2/neu gene by CISH was observed in 4 of the 36 (11.1% ) cases.Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis ( P = 0.030 and P = 0.002,respectively),while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis ( P < 0.05 ).In 13patients with Her-2/neu protein over-expression,the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs.42 months,P = 0.370 ).Conclusion Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome,and might reduce the chemotherapy sensitivity.
